Abstract
Oral epithelial dysplasia (OED) is a potentially malignant histopathological diagnosis given to lesions of the oral cavity that are at risk of progression to malignancy. Manual grading of OED is subject to substantial variability and does not reliably predict prognosis, potentially resulting in sub-optimal treatment decisions. We developed a Transformer-based artificial intelligence (AI) pipeline for the prediction of malignant transformation from whole-slide images (WSIs) of Haematoxylin and Eosin (H&E) stained OED tissue slides, named ODYN (Oral Dysplasia Network). ODYN can simultaneously classify OED and assign a predictive score (ODYN-score) to quantify the risk of malignant transformation. The model was trained on a large cohort using three different scanners (Sheffield, 358 OED WSIs, 105 control WSIs) and externally validated on cases from three independent centres (Birmingham and Belfast, UK, and Piracicaba, Brazil; 108 OED WSIs). Model testing yielded an F1-score of 0.96 for classification of dysplastic vs non-dysplastic slides, and an AUROC of 0.73 for malignancy prediction, gaining comparable results to clinical grading systems. With further large-scale prospective validation, ODYN promises to offer an objective and reliable solution for assessing OED cases, ultimately improving early detection and treatment of oral cancer.
Competing Interest Statement
NMR is the co-founder, CEO and CSO, and a shareholder of Histofy Ltd. He is also the GSK Chair of Computational Pathology and is in receipt of research funding from GSK and AstraZeneca. SAK is a shareholder of Histofy Ltd. All other authors have no competing interests to declare.
Funding Statement
This study was supported by a Cancer Research UK Early Detection Project Grant, as part of the ANTICIPATE study (grant no. C63489/A29674) in addition to funding from the National Institute for Health Research (award no. NIHR300904). ALDA was funded by The São Paulo Research Foundation (grant no. 2021/14585-7).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was obtained from the NHS Health Research Authority West Midlands (18/WM/0335), and experiments were conducted in compliance with the Declaration of Helsinki. Data collected were fully anonymised.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
5. Data Availability
We are unable to share the whole slide images and clinical data, due to restrictions in the ethics applications.
